Lorlatinib continues to deliver exceptional long-term disease control in previously untreated ALK-positive advanced non-small cell lung cancer, but new translational data from CROWN are beginning to clarify why a minority of patients still progress early (OncoDaily) - Oct 24, 2026 - "At ESMO Congress 2026, an exploratory circulating tumor DNA analysis from the phase III CROWN trial showed that early progression on lorlatinib was associated with greater baseline genomic complexity, higher blood-based tumor mutational burden, more frequent TP53 alterations, and enrichment of inflammatory-response pathways. Importantly, paired baseline and end-of-treatment analyses did not identify newly acquired ALK resistance mutations in patients progressing on lorlatinib."
P3 data • Non Small Cell Lung Cancer
|